

Atovaquone and proguanil:

Class: Antimalarial Agent.

Indications: Prevention or treatment of acute, uncomplicated *P. falciparum* malaria.

Available dosage form in the hospital: PROGUANIL 100MG +ATOVAQUONE 250MG TAB.

Trade Names:

Dosage:

Prevention of malaria: Oral: Atovaquone/proguanil 250 mg/100 mg once daily; start 1-2 days prior to entering a malaria-endemic area, continue throughout the stay and for 7 days after returning.

Treatment of acute malaria: Oral: Atovaquone/proguanil 1 g/400 mg as a single dose, once daily for 3 consecutive days

Dosing: Renal Impairment :

No dosage adjustment required in mild-to-moderate renal impairment. Contraindicated as prophylaxis in severe renal impairment ($Cl_{cr} < 30$ mL/minute). May use for 3-day treatment in patients with severe renal impairment if benefit outweighs risk

Common side effect:

Gastrointestinal: Abdominal pain (17%), nausea (12%), vomiting , Diarrhea

Hepatic: Transaminase increases (ALT 27%, AST 17%; increased LFT values typically normalized after ~4 weeks)

Central nervous system: Headache , dizziness .

Dermatologic: Pruritus .

Neuromuscular & skeletal: Weakness .

Pregnancy Risk Factor: C